An Intermediate Expanded Use Trial of DFMO(eflornithine HCl)
Objective
Primary Objective: To provide DFMO in an expanded use setting to subjects in the described disease categories. Each disease type will be evaluated after 10 patients enrolled for suggestion of activity and initiation of Phase II study.
Secondary Objective: To continue to determine the safety and tolerability of DFMO as a single agent and in combination with standard medications in pediatric and young adult cancer patients.
